Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Euthymics Bioscience Inc.

Headquarters: Cambridge, MA, United States of America
Year Founded: 2009
Status: Private

BioCentury | Mar 3, 2017
Company News

Otsuka acquiring ADHD company Neurovance

BioCentury | Dec 15, 2016
Company News

Management tracks

BioCentury | Feb 2, 2015
Emerging Company Profile

Three's company

How the serotonin component of Neurovance's ADHD candidate could set it apart
BioCentury | Nov 18, 2013
Product Development

New designs in depression

Alkermes advancing new trial design to eliminate placebo problems in depression
BioCentury | Jun 24, 2013
Company News

Epirus management update

BioCentury | Jun 3, 2013
Clinical News

Amitifadine: Phase IIb/IIIa data

BioCentury | Oct 22, 2012
Clinical News

Amitifadine: Completed Phase IIb/IIIa enrollment

BioCentury | Oct 22, 2012
Clinical News

EB-1020: Phase I data

BioCentury | Oct 22, 2012
Finance

Maximizing depression

Euthymics spins out Neurovance; clears way for potential deal in depression
BioCentury | Oct 19, 2012
Company News

Euthymics' Neurovance spinout raises $7M

Items per page:
1 - 10 of 24